195 completed, 26 terminated, 18 unknown, 9 recruiting. 99 Phase 3, 57 Phase 2, 38 Phase 4, 31 Phase 1, 25 Not applicable.
Follow Human Growth Hormone: new trials by email Literature Review of Human Growth Hormone trials Research Report on Human Growth Hormone
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Human Models of Selective Insulin Resistance: Pancreatic Clamp Insulin human, Octreotide Acetate, Glucagon - Insulin Resistance, Hyperinsulinemia | Phase 1 | Not yet recruiting | Columbia University | 36 | 2027-01-01 | 2026-02-06 |
| Phase 3 Study to Evaluate the Efficacy and Safety of Human Growth Hormone Injection (Sinotropin AQ) for the Treatment of Children With Idiopathic Short Stature Human Growth Hormone (hGH) - Idiopathic Short Stature (ISS) | Phase 3 | Not yet recruiting | Zhongshan Sansure Hygene Biomedicine Co., Ltd. | 240 | 2026-09-01 | 2026-09-11 |
| A Study to Learn How Different Injector Pens Affect the Study Medicine Called Genotropin (Somatropin) Delivery and Taken up Into the Blood in Healthy Adults Marketed Genotropin Pen 12, New Genotropin Injector Pen, Genotropin 4mg - Healthy | Phase 1 | Completed | Pfizer | 27 | 2026-04-22 | 2026-08-10 |
| Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite Athletes Testosterone Enanthate, Testosterone Cypionate, Testosterone Propionate - Safety and Impact of Medically Supervised Performance Enhancing Substance Usage in Healthy Elite Athletes | Not applicable | Enrolling by invitation | Enhanced Emirates Limited | 60 | 2026-03-12 | 2026-05-06 |
| A Study of GenSci134 in Children With Growth Hormone Deficiency (PGHD) GenSci134 Injection, Recombinant Human Growth Hormone Injection(Norditropin® FlexPro®) - Pediatric Growth Hormone Deficiency | Phase 1 / Phase 2 | Not yet recruiting | Changchun GeneScience Pharmaceutical Co., Ltd. | 128 | 2026-03-06 | 2026-03-04 |
| A Study (Phase 1b/2) of GenSci134 in Children With Idiopathic Short Stature (ISS) GenSci134 Injection, Recombinant Human Growth Hormone Injection(Norditropin® FlexPro®) - Idiopathic Short Stature | Phase 1 / Phase 2 | Not yet recruiting | Changchun GeneScience Pharmaceutical Co., Ltd. | 128 | 2026-03-06 | 2026-03-04 |
| Comparison of Weekly Somatrogon to Daily Genotropin in Children Born Small for Gestational Age or With Idiopathic Short Stature. Somatrogon, Genotropin - ISS, SGA | Phase 3 | Recruiting | Rabin Medical Center | 254 | 2026-02-01 | 2026-04-30 |
| Effects of Ketone Bodies on Insulin Sensitivity Growth Hormone, Human, Oral ketone supplement (KetoAid®, KE4), Saline infusion (placebo) - Insulin Resistance, Obesity & Overweight | Not applicable | Recruiting | University of Aarhus | 10 | 2025-12-02 | 2026-01-22 |
| Recombinant Human Growth Hormone (rHGH) for Knee Osteoarthritis (KORR) Somatropin (recombinant human growth hormone), bacteriostatic saline placebo - Knee Osteoarthritis (Knee OA), Knee Osteoarthritis (OA) | Phase 1 / Phase 2 | Active not recruiting | Dr. David Wasserstein | 34 | 2025-10-31 | 2026-07-31 |
| Growth Hormone and Dehydroepiandrosterone Role in Vitro Fertilization Somatropin (4IU for 1 month) plus, folic acid 400 mcg per day., DHEA plus folic acid 400mcg per day, control group - Infertility, Infertility (IVF Patients) | Phase 2 / Phase 3 | Recruiting | Beni-Suef University | 165 | 2025-10-10 | 2026-01-07 |
| A Clinical Study of GenSci134 in Healthy Adults and Adult Growth Hormone Deficiency(AGHD) GenSci134, Placebo, Recombinant Human Growth Hormone Injection (Norditropin®) - Safety, Tolerability | Phase 1 | Recruiting | Changchun GeneScience Pharmaceutical Co., Ltd. | 64 | 2025-06-09 | 2026-04-14 |
| Functional Connectome in Prader-Willi Syndrome: Neuroimaging and AI to Assess Therapeutic Impact GH treatment (Somatropin), Eating - Prader Willi Syndrome, Hyperphagia | Completed | Corporacion Parc Tauli | 101 | 2025-03-01 | 2025-04-01 | |
| Growth Hormone Replacement Therapy in Veterans With Mild Traumatic Brain Injury (mTBI) and Adult Growth Hormone Deficiency (AGHD) Somatropin, Placebo - Adult Growth Hormone Deficiency, Mild Traumatic Brain Injury | Phase 3 | Recruiting | VA Office of Research and Development | 172 | 2025-01-13 | 2026-10-13 |
| A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature Vosoritide Injection, Human Growth Hormone, Placebo - Idiopathic Short Stature | Phase 2 | Recruiting | BioMarin Pharmaceutical | 100 | 2024-10-21 | 2026-05-22 |
| Dexamethasone/Pancreatic Clamp P&F Insulin human, Octreotide Acetate, Glucagon - Insulin Resistance, Prediabetic State | Phase 1 | Withdrawn | Columbia University | 2024-07-01 | 2024-07-10 | |
| Growth Hormone Replacement in Veterans With GWI and AGHD (GWIT) Recombinant human growth hormone - Gulf War Syndrome, Adult Growth Hormone Deficiency | Phase 2 | Recruiting | Baylor College of Medicine | 20 | 2024-03-11 | 2026-05-08 |
| Randomized Clinical Trial of Two Different Initial Growth Hormone Doses in Children Somatropin - Growth Disorders, Growth Failure | Phase 3 | Recruiting | Northwell Health | 50 | 2023-12-10 | 2026-10-21 |
| A Study to Investigate Efficacy and Safety of Weekly PEG-somatropin (GenSci004) in Treatment Naive Children With Growth Hormone Deficiency GenSci004, Genotropin - GHD | Phase 3 | Unknown | Changchun GeneScience Pharmaceutical Co., Ltd. | 162 | 2023-12-01 | 2023-09-11 |
| Pancreatic Clamp in NAFLD Insulin human, Octreotide Acetate, Glucagon - Insulin Resistance, Prediabetic State | Phase 1 | Completed | Columbia University | 18 | 2023-08-29 | 2026-01-12 |
| The Effect of Myo-inositol, Somatropin, and DHEA on Poor Ovarian Responders myo-inositol, Somatropin, Dehydroepiandrosterone - Poor Responders | Phase 2 / Phase 3 | Unknown | Beni-Suef University | 300 | 2023-07-30 | 2023-07-18 |
Showing 20 of 268. Sign in to see all of them.
Dwarfism, Pituitary (80) · Turner Syndrome (24) · Dwarfism (15) · Genetic Diseases, Inborn (15) · Growth Disorders (15) · Insulin Resistance (13) · HIV Infections (8) · Noonan Syndrome (8) · Hypopituitarism (7) · Brain Injuries, Traumatic (6) · Endocrine System Diseases (6) · Failure to Thrive (6) · Obesity (6) · Prader-Willi Syndrome (6) · Infertility (5)
Novo Nordisk A/S (58) · Pfizer (23) · Eli Lilly and Company (13) · Merck KGaA, Darmstadt, Germany (12) · University of Aarhus (10) · EMD Serono (8) · Massachusetts General Hospital (8) · Changchun GeneScience Pharmaceutical Co., Ltd. (7) · Ferring Pharmaceuticals (6) · The University of Texas Medical Branch, Galveston (5) · Federico II University (4) · Genentech, Inc. (4) · Ascendis Pharma A/S (3) · Baylor College of Medicine (3) · Columbia University (3)
United States (87) · France (42) · Germany (37) · Denmark (25) · Spain (25) · Japan (22) · Israel (18) · United Kingdom (18) · Italy (17) · Canada (16) · Sweden (16) · Poland (15) · South Korea (15) · Hungary (13) · China (11)
Dina M Dakhly, MD (3) · Byung Kyu Suh, M.D., Ph.D. (2) · Chang Jong Kim, M.D., Ph.D. (2) · Cheol Woo Ko, M.D., Ph.D. (2) · Choong Ho Shin, M.D., Ph.D. (2) · Christopher L Mendias, PhD, ATC (2)
PMID 29029101, PMID 36380045, PMID 18395480, PMID 22508317, PMID 22788856, PMID 23658497, PMID 31305924, PMID 31668393, PMID 31972476, PMID 33571362, PMID 33709288, PMID 33864240, PMID 34808697, PMID 36947589, PMID 40919719, PMID 41285480, PMID 10022400, PMID 10199767, PMID 10199774, PMID 10372687, PMID 10487666, PMID 10518081, PMID 10599727, PMID 10599729, PMID 11061539, PMID 11155088, PMID 11207626, PMID 11207640, PMID 11273062, PMID 11344175, PMID 11531927, PMID 11739431, PMID 11889170, PMID 12466334, PMID 12519875, PMID 12629094, PMID 12915640, PMID 12924350, PMID 14571231, PMID 14671164, PMID 15076238, PMID 15126541, PMID 15355453, PMID 15579750, PMID 15585563, PMID 15671089, PMID 15784709, PMID 15900109, PMID 15985481, PMID 16203673
2008 (4), 2018 (4), 2005 (3), P30DK063608 (3), 2015 (2), 2004 (1), 2014 (1), 2016 (1), 2017 (1), 2019 (1), K12DK133995 (1), P50GM060338 (1), R01AI043864 (1), R01AR050618 (1), R01DK063639 (1)